股本结构
单位：万股
| 公告日期 | 2025-10-30 | 2025-10-30 | 2025-08-12 | 2025-08-14 | 2025-07-21 | 2025-06-23 |
|---|---|---|---|---|---|---|
| 证券总股本 | 13742.91 | 13160.55 | 9926.45 | 9218.00 | 6049.01 | 5099.85 |
| 普通股本 | 13742.91 | 13160.55 | 9926.45 | 9218.00 | 6049.01 | 5099.85 |
| 优先股 | 未披露 | 0.20 | 0.20 | 0.20 | 未披露 | 0.20 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-10-29 | 2025-09-30 | 2025-08-08 | 2025-06-30 | 2025-06-18 | 2025-06-16 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-10-30 | 13742.91 | 未披露 | 定期报告 | 2025-10-29 |
| 2025-10-30 | 13160.55 | 0.20 |
更多>>
From June 30, 2025 to September 30, 2025
Cancelled common stock
Issuance of common stock under Lincoln Park Purchase Agreement, net issuance costs
Exercise of March 2025 Series B Warrants
Exercise of pre-funded warrants
|
2025-09-30 |
| 2025-08-12 | 9926.45 | 0.20 | 定期报告 | 2025-08-08 |
| 2025-08-14 | 9218.00 | 0.20 |
更多>>
From March 31, 2025 to June 30, 2025
Exercise of March 2025 Series B Warrants
Exercise of pre-funded warrants
Cancellation of common stock
Issuance of common stock under Lincoln Park Purchase Agreement, net issuance costs
|
2025-06-30 |
| 2025-07-21 | 6049.01 | 未披露 | 定期报告 | 2025-06-18 |
| 2025-06-23 | 5099.85 | 0.20 | 定期报告 | 2025-06-16 |
| 2025-05-30 | 3271.71 | 未披露 | 定期报告 | 2025-05-27 |
| 2025-05-30 | 1699.96 | 0.20 |
更多>>
From December 31, 2024 to March 31, 2025
Exercise of pre-funded warrants
Exercise of Series B Warrants from May 2024 PIPE
Issuance of common stock, prefunded warrants and warrants for debt repayment
|
2025-03-31 |
| 2025-03-31 | 1699.96 | 未披露 | 定期报告 | 2025-03-21 |
| 2025-04-10 | 1178.51 | 未披露 | 定期报告 | 2025-03-04 |
| 2024-11-14 | 589.63 | 0.20 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of pre-funded warrants
|
2024-09-30 |
| 2024-08-14 | 589.63 | 未披露 | 定期报告 | 2024-08-09 |
| 2024-08-14 | 570.42 | 0.20 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock
|
2024-06-30 |
| 2024-05-15 | 570.42 | 未披露 | 定期报告 | 2024-05-10 |
| 2024-05-15 | 426.42 | 0.20 |
更多>>
From December 31, 2023 to March 31, 2024
Purchase of treasury stock
|
2024-03-31 |
| 2024-03-05 | 427.61 | 未披露 | 定期报告 | 2024-02-26 |
| 2024-03-05 | 444.41 | 0.20 |
更多>>
From December 31,2022 to December 31,2023
Sale of common stock, net
Issuance of common stock for in process research and development
Fractional adjustment
|
2023-12-31 |
| 2023-10-31 | 452.27 | 0.20 |
更多>>
From June 30, 2023 to September 30, 2023
Sale of common stock, net
Issuance of common stock for in process research and development
|
2023-09-30 |
| 2023-08-14 | 287.96 | 0.20 |
更多>>
From March 31, 2023 to June 30, 2023
Fractional adjustment
Redemption of Series F preferred stock
Sale of common stock, net
|
2023-06-30 |
| 2023-04-28 | 249.33 | 未披露 |
更多>>
1.Plus Therapeutics, Inc. to implement the 1-for-15 reverse split of its common stock will be effective as of 12:01 a.m. (Eastern time) on May 1, 2023.
|
2023-05-01 |
| 2023-04-28 | 3740.00 | 未披露 | 定期报告 | 2023-04-28 |
| 2023-04-20 | 3669.09 | 未披露 | 定期报告 | 2023-04-18 |
| 2023-04-20 | 3612.38 | 0.20 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of Series F preferred stock
Sale of common stock, net
|
2023-03-31 |
| 2023-03-07 | 3541.82 | 未披露 | 定期报告 | 2023-03-03 |
| 2023-02-23 | 3510.99 | 未披露 | 定期报告 | 2023-02-17 |
| 2023-02-23 | 3360.14 | 0.20 |
更多>>
From December 31, 2021 to December 31, 2022
Sale of common stock, net
|
2022-12-31 |
| 2022-10-20 | 3360.14 | 未披露 | 定期报告 | 2022-10-14 |
| 2022-10-20 | 3257.00 | 0.20 |
更多>>
From June 30, 2022 to September 30, 2022
Sale of common stock, net
|
2022-09-30 |
| 2022-09-09 | 3257.00 | 未披露 | 定期报告 | 2022-09-06 |
| 2022-08-09 | 2310.51 | 0.20 | 定期报告 | 2022-08-02 |
| 2022-08-09 | 2261.24 | 未披露 | 定期报告 | 2022-08-01 |
| 2022-07-21 | 2253.20 | 未披露 | 定期报告 | 2022-07-14 |
| 2022-07-21 | 2246.87 | 0.20 |
更多>>
From March 31, 2022 to June 30, 2022
Sale of common stock, net
|
2022-06-30 |
| 2022-04-21 | 2219.76 | 0.20 |
更多>>
From December 31, 2021 to March 31, 2022
Sale of common stock, net
|
2022-03-31 |
| 2022-02-24 | 2217.50 | 未披露 | 定期报告 | 2022-02-18 |
| 2022-01-14 | 2117.50 | 未披露 | 定期报告 | 2022-01-13 |
| 2022-02-24 | 1551.00 | 0.20 |
更多>>
From December 31, 2020 to December 31, 2021
Sale of common stock, net of offering costs of $0.3 million
Issuance of common stock for exercise of warrants
Conversion of Series B convertible preferred stock into common stock
|
2021-12-31 |
| 2021-10-21 | 1536.00 | 0.20 |
更多>>
From June 30, 2021 to September 30, 2021
Sale of common stock, net of offering cost
|
2021-09-30 |
| 2021-09-03 | 1531.00 | 未披露 | 定期报告 | 2021-09-02 |
| 2021-07-22 | 1208.75 | 0.20 |
更多>>
From March 31, 2021 to June 30, 2021
Sale of common stock, net of offering cost of $17,000
|
2021-06-30 |
| 2021-07-06 | 1023.55 | 未披露 | 定期报告 | 2021-04-09 |
| 2021-04-22 | 1018.05 | 0.20 |
更多>>
from December 31, 2020 to March 31, 2021
Conversion of Series B Convertible Preferred Stock into common stock
Sale of common stock, net of offering cost of $0.1 million
Issuance of common stock for exercise of warrants
|
2021-03-31 |
| 2021-04-05 | 922.19 | 未披露 | 定期报告 | 2021-03-22 |
| 2021-02-26 | 916.69 | 未披露 | 定期报告 | 2021-02-24 |
| 2021-02-22 | 2110.62 | 未披露 | 定期报告 | 2021-02-16 |
| 2021-02-22 | 674.90 | 0.20 |
更多>>
From December 31,2019 to December 31,2020
Issuance of common stock, net of offering costs of $0.6 million
Issuance of common stock for exercise of warrants
Issuance of common stock for in process research and development acquired from NanoTx Therapeutics
Conversion of Series B convertible preferred stock into common stock
|
2020-12-31 |
| 2020-10-29 | 477.96 | 0.20 | 定期报告 | 2020-10-27 |
| 2020-10-22 | 477.96 | 未披露 | 定期报告 | 2020-10-14 |
| 2020-10-22 | 459.14 | 0.20 |
更多>>
From June 30, 2020 to September 30, 2020
Conversion of Series B convertible preferred stock into common stock
Issuance of common stock for exercise of warrants
|
2020-09-30 |
| 2020-10-29 | 459.14 | 未披露 | 定期报告 | 2020-09-29 |
| 2020-08-10 | 427.39 | 未披露 | 定期报告 | 2020-08-03 |
| 2020-08-10 | 427.39 | 0.20 |
更多>>
from March 31, 2020 to June 30, 2020
Issuance of common stock for exercise of warrants
Issuance of common stock for in process research and development acquired from NanoTx Therapeutics
|
2020-06-30 |
| 2020-05-13 | 411.14 | 未披露 | 定期报告 | 2020-05-08 |
| 2020-03-30 | 388.06 | 0.20 |
更多>>
from December 31, 2018 to December 31, 2019
Sale of common stock, net
Conversion of Series B and Series C Convertible Preferred Stock into common stock
Sale of common stock, pre-funded warrants and warrants for common stock, net of offering costs of $0.6 million
Exercise of warrants
|
2019-12-31 |
| 2019-11-14 | 377.06 | 未披露 | 定期报告 | 2019-11-08 |
| 2019-11-14 | 284.16 | 0.20 |
更多>>
From June 30, 2019 to September 30, 2019
Sale of common stock, pre-funded warrants and warrants for common stock,net of offering costs of $0.6 million
Conversion of Series B and Series C Convertible Preferred Stock into common stock
Exercise of warrants
|
2019-09-30 |
| 2019-09-25 | 344.31 | 未披露 | 定期报告 | 2019-09-25 |
| 2019-07-29 | 40.00 | 未披露 |
更多>>
The reverse stock split will automatically combine every 50 shares of the Company's common stock into one issued and outstanding share without any change in the par value of the shares. Following the reverse stock split, the number of outstanding shares of the Company's common stock is anticipated to be proportionally reduced from approximately 22.2 million to approximately 0.4 million.
|
2019-08-06 |
| 2019-05-14 | 2215.58 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-05-14 | 2190.58 | 0.45 |
更多>>
from December 31, 2018 to March 31, 2019
Sale of common stock, net
Conversion of Series C Convertible Preferred Stock into common stock
|
2019-03-31 |
| 2019-04-19 | 2190.58 | 未披露 | 定期报告 | 2019-03-29 |
| 2019-03-29 | 1632.61 | 未披露 | 定期报告 | 2019-01-31 |
| 2019-03-29 | 1483.04 | 0.46 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of Series C Convertible Preferred Stock into common stock, net
Conversion of Series C Convertible Preferred Stock into common stock
Conversion of Series B Convertible Preferred Stock into common stock
|
2018-12-31 |
| 2018-11-14 | 1320.14 | 未披露 | 定期报告 | 2018-10-31 |
| 2018-11-14 | 1169.13 | 0.46 | 定期报告 | 2018-09-30 |
| 2018-09-21 | 1119.27 | 未披露 | 定期报告 | 2018-09-15 |
| 2018-08-14 | 770.79 | 未披露 | 定期报告 | 2018-07-31 |
| 2018-08-14 | 617.61 | 0.12 | 定期报告 | 2018-06-30 |
| 2018-05-24 | 620.00 | 未披露 |
更多>>
Cytori Therapeutics (NASDAQ:CYTX) ("Cytori" or the "Company") today announced that the Company effected a reverse stock split that became effective on May 23, 2018 at a ratio of one-for-ten, and that the Company's common stock will commence trading on a post-split basis beginning on May 24, 2018. The Company received the requisite stockholder approval for the reverse stock split on May 18, 2018. The new CUSIP number for the Company's common stock will be 23283K402.
|
2018-05-24 |
| 2018-05-11 | 6162.28 | 未披露 | 定期报告 | 2018-04-30 |
| 2018-05-11 | 6161.38 | 0.12 | 定期报告 | 2018-03-31 |
| 2018-04-27 | 6161.38 | 未披露 | 定期报告 | 2018-03-21 |
| 2018-04-06 | 6160.78 | 0.24 | 定期报告 | 2018-02-28 |
| 2018-03-09 | 5981.96 | 未披露 | 定期报告 | 2018-01-31 |
| 2018-03-09 | 5782.57 | 0.24 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of Series B Convertible Preferred Stock into common stock, net
Conversion of Series B Convertible Preferred Stock into common stock
Issuance of common stock under employee stock purchase plan
Sale of common stock, net
Issuance of common stock as part of Azaya Therapeutics acquisition, net
|
2017-12-31 |
| 2017-11-09 | 3511.94 | 未披露 | 定期报告 | 2017-10-31 |
| 2017-11-09 | 3471.63 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-11 | 3471.63 | 未披露 | 定期报告 | 2017-08-01 |
| 2017-08-10 | 3332.84 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-12 | 3247.82 | 未披露 | 定期报告 | 2017-04-30 |
| 2017-05-12 | 2376.74 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-04-10 | 2367.24 | 未披露 | 定期报告 | 2017-03-23 |
| 2017-03-27 | 2356.84 | 未披露 | 定期报告 | 2017-02-28 |
| 2017-03-24 | 2196.64 | 未披露 | 定期报告 | 2017-01-31 |
| 2017-03-24 | 2170.79 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Issuance of common stock under employee stock purchase plan
Sale of common stock, net
On May 10, 2016, the Company effected a reverse stock split at a ratio of 1-for-15. All share and per share information presented herein has been retroactively restated to reflect the reverse split.
|
2016-12-31 |
| 2016-12-30 | 2170.65 | 未披露 | 定期报告 | 2016-12-28 |
| 2016-11-09 | 2050.06 | 未披露 | 定期报告 | 2016-10-31 |
| 2016-11-09 | 2049.51 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-09-30 | 2049.44 | 未披露 | 定期报告 | 2016-08-31 |
| 2016-08-05 | 2049.26 | 未披露 | 定期报告 | 2016-07-31 |
| 2016-08-04 | 2049.26 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-25 | 1331.07 | 未披露 |
更多>>
On May 10, 2016, the Company effected a reverse stock split at a ratio of 1-for-15. All share and per share information presented herein has been retroactively restated to reflect the reverse split.
|
2016-05-12 |
| 2016-03-15 | 19775.73 | 未披露 | 定期报告 | 2016-03-11 |
| 2016-03-11 | 19518.65 | 未披露 | 定期报告 | 2016-01-31 |
| 2016-03-11 | 19505.84 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Conversion of Series A 3.6% Convertible Preferred Stock into common stock
Issuance of common stock under stock option plan and employee stock purchase plan
Issuance of common stock under stock warrant agreement, net
Sale of common stock, net
|
2015-12-31 |
| 2015-11-06 | 15848.52 | 未披露 | 定期报告 | 2015-10-31 |
| 2015-11-05 | 15846.86 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-06 | 15095.82 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-07-02 | 15092.00 | 未披露 | 定期报告 | 2015-06-16 |
| 2015-05-11 | 12576.36 | 未披露 | 定期报告 | 2015-04-30 |
| 2015-05-11 | 11409.74 | 0.03 | 定期报告 | 2015-03-31 |
| 2015-03-16 | 10818.14 | 未披露 | 定期报告 | 2015-02-28 |
| 2015-03-16 | 9934.84 | 0.53 |
更多>>
From December 31,2013 to December 31,2014
Issuance of common stock under stock option plan and employee stock purchase plan
Sale of common stock, net
Issuance of Series A 3.6% Convertible Preferred Stock, net
Conversion of Series A 3.6% Convertible Preferred Stock into common stock
Issuance of common stock under stock warrant agreement
|
2014-12-31 |
| 2014-11-07 | 9244.92 | 未披露 | 定期报告 | 2014-10-31 |
| 2014-11-06 | 8357.42 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-11 | 7954.18 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-06-12 | 7950.71 | 未披露 | 定期报告 | 2014-06-04 |
| 2014-05-12 | 7545.86 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-02-11 | 7544.82 | 未披露 | 定期报告 | 2014-01-31 |
| 2014-03-14 | 7130.54 | 未披露 |
更多>>
From December 31,2012 to December 31,2013
Issuance of common stock under stock option plan and employee stock purchase plan
Sale of common stock, net
|
2013-12-31 |
| 2013-11-19 | 7527.05 | 未披露 | 定期报告 | 2013-11-14 |
| 2013-11-07 | 6727.05 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-08-08 | 6723.56 | 未披露 | 定期报告 | 2013-06-30 |
| 2013-05-10 | 6718.31 | 未披露 | 定期报告 | 2013-04-30 |
| 2013-05-10 | 6717.31 | 未披露 | 定期报告 | 2013-03-31 |
| 2013-03-15 | 6717.31 | 未披露 | 定期报告 | 2013-02-28 |
| 2013-03-15 | 6591.41 | 未披露 |
更多>>
from December 31, 2011 to December 31, 2012
Issuance of common stock under stock option plan and employee stock purchase plan
Issuance of common stock under stock warrant agreement
Sale of common stock, net
|
2012-12-31 |
| 2012-11-09 | 5883.19 | 未披露 | 定期报告 | 2012-10-31 |
| 2012-11-08 | 5872.06 | 未披露 | 定期报告 | 2012-09-30 |
| 2012-08-09 | 5871.12 | 未披露 | 定期报告 | 2012-07-31 |
| 2012-08-09 | 5870.69 | 未披露 | 定期报告 | 2012-06-30 |
| 2012-05-10 | 5868.64 | 未披露 | 定期报告 | 2012-04-30 |
| 2012-05-09 | 5842.86 | 未披露 | 定期报告 | 2012-03-31 |
| 2012-03-13 | 5792.86 | 未披露 | 定期报告 | 2012-02-29 |
| 2012-03-08 | 5659.47 | 未披露 | 定期报告 | 2011-12-31 |
| 2011-11-08 | 5533.47 | 未披露 | 定期报告 | 2011-10-31 |
| 2011-11-08 | 5483.47 | 未披露 | 定期报告 | 2011-09-30 |
| 2011-08-09 | 5379.65 | 未披露 | 定期报告 | 2011-07-29 |
| 2011-08-09 | 5247.02 | 未披露 | 定期报告 | 2011-06-30 |
| 2011-05-06 | 5247.02 | 未披露 | 定期报告 | 2011-04-29 |
| 2011-05-06 | 5213.44 | 未披露 | 定期报告 | 2011-03-31 |
| 2011-03-11 | 5196.37 | 未披露 | 定期报告 | 2011-02-28 |
| 2011-03-11 | 5195.53 | 未披露 |
更多>>
Issuance of common stock under stock option plan
Issuance of common stock under stock warrant agreement
Sale of common stock
|
2010-12-31 |
| 2010-11-08 | 5050.92 | 未披露 | 定期报告 | 2010-10-31 |
| 2010-11-08 | 4590.92 | 未披露 | 定期报告 | 2010-09-30 |
| 2010-08-09 | 4590.59 | 未披露 | 定期报告 | 2010-07-31 |
| 2010-08-09 | 4590.06 | 未披露 | 定期报告 | 2010-06-30 |
| 2010-05-06 | 4507.51 | 未披露 | 定期报告 | 2010-04-30 |
| 2010-05-06 | 4452.46 | 未披露 | 定期报告 | 2010-03-31 |
| 2010-03-12 | 4282.60 | 未披露 | 定期报告 | 2010-02-28 |
| 2010-03-12 | 4003.93 | 未披露 |
更多>>
from December 31, 2008 to December 31, 2009
Issuance of common stock under stock option plan
Issuance of common stock under stock warrant agreement
Sale of common stock
|
2009-12-31 |
| 2009-03-06 | 2931.34 | 未披露 | 定期报告 | 2009-02-28 |
| 2009-03-06 | 2930.34 | 未披露 |
更多>>
from December 31, 2007 to December 31, 2008
Issuance of common stock under stock option plan
Sale of common stock
|
2008-12-31 |
| 2008-03-14 | 2510.39 | 未披露 | 定期报告 | 2008-02-29 |
| 2008-03-14 | 2408.94 | 未披露 |
更多>>
from December 31, 2006 to December 31, 2007
Issuance of common stock under stock option plan
Sale of common stock
Sale of treasury stock
|
2007-12-31 |
| 2007-04-02 | 2253.46 | 未披露 | 定期报告 | 2007-03-01 |
| 2007-04-02 | 1873.94 | 未披露 |
更多>>
from December 31, 2005 to December 31, 2006
Issuance of common stock under stock option plan
Compensatory common stock awards
Issuance of common stock
Stock issued for license amendment
|
2006-12-31 |
| 2006-03-30 | 1540.19 | 未披露 | 定期报告 | 2006-01-31 |
| 2006-03-30 | 1532.14 | 未披露 |
更多>>
from December 31, 2004 to December 31, 2005
Issuance of common stock under stock option plan
Issuance of common stock under stock warrant agreement
Compensatory common stock awards
Issuance of common stock to Olympus
|
2005-12-31 |
From June 30, 2025 to September 30, 2025
Cancelled common stock
Issuance of common stock under Lincoln Park Purchase Agreement, net issuance costs
Exercise of March 2025 Series B Warrants
Exercise of pre-funded warrants
From March 31, 2025 to June 30, 2025
Exercise of March 2025 Series B Warrants
Exercise of pre-funded warrants
Cancellation of common stock
Issuance of common stock under Lincoln Park Purchase Agreement, net issuance costs
From December 31, 2024 to March 31, 2025
Exercise of pre-funded warrants
Exercise of Series B Warrants from May 2024 PIPE
Issuance of common stock, prefunded warrants and warrants for debt repayment
From June 30, 2024 to September 30, 2024
Exercise of pre-funded warrants
From March 31, 2024 to June 30, 2024
Issuance of common stock
From December 31, 2023 to March 31, 2024
Purchase of treasury stock
From December 31,2022 to December 31,2023
Sale of common stock, net
Issuance of common stock for in process research and development
Fractional adjustment
From June 30, 2023 to September 30, 2023
Sale of common stock, net
Issuance of common stock for in process research and development
From March 31, 2023 to June 30, 2023
Fractional adjustment
Redemption of Series F preferred stock
Sale of common stock, net
1.Plus Therapeutics, Inc. to implement the 1-for-15 reverse split of its common stock will be effective as of 12:01 a.m. (Eastern time) on May 1, 2023.
From December 31, 2022 to March 31, 2023
Issuance of Series F preferred stock
Sale of common stock, net
From December 31, 2021 to December 31, 2022
Sale of common stock, net
From June 30, 2022 to September 30, 2022
Sale of common stock, net
From March 31, 2022 to June 30, 2022
Sale of common stock, net
From December 31, 2021 to March 31, 2022
Sale of common stock, net
From December 31, 2020 to December 31, 2021
Sale of common stock, net of offering costs of $0.3 million
Issuance of common stock for exercise of warrants
Conversion of Series B convertible preferred stock into common stock
From June 30, 2021 to September 30, 2021
Sale of common stock, net of offering cost
From March 31, 2021 to June 30, 2021
Sale of common stock, net of offering cost of $17,000
from December 31, 2020 to March 31, 2021
Conversion of Series B Convertible Preferred Stock into common stock
Sale of common stock, net of offering cost of $0.1 million
Issuance of common stock for exercise of warrants
From December 31,2019 to December 31,2020
Issuance of common stock, net of offering costs of $0.6 million
Issuance of common stock for exercise of warrants
Issuance of common stock for in process research and development acquired from NanoTx Therapeutics
Conversion of Series B convertible preferred stock into common stock
From June 30, 2020 to September 30, 2020
Conversion of Series B convertible preferred stock into common stock
Issuance of common stock for exercise of warrants
from March 31, 2020 to June 30, 2020
Issuance of common stock for exercise of warrants
Issuance of common stock for in process research and development acquired from NanoTx Therapeutics
from December 31, 2018 to December 31, 2019
Sale of common stock, net
Conversion of Series B and Series C Convertible Preferred Stock into common stock
Sale of common stock, pre-funded warrants and warrants for common stock, net of offering costs of $0.6 million
Exercise of warrants
From June 30, 2019 to September 30, 2019
Sale of common stock, pre-funded warrants and warrants for common stock,net of offering costs of $0.6 million
Conversion of Series B and Series C Convertible Preferred Stock into common stock
Exercise of warrants
The reverse stock split will automatically combine every 50 shares of the Company's common stock into one issued and outstanding share without any change in the par value of the shares. Following the reverse stock split, the number of outstanding shares of the Company's common stock is anticipated to be proportionally reduced from approximately 22.2 million to approximately 0.4 million.
from December 31, 2018 to March 31, 2019
Sale of common stock, net
Conversion of Series C Convertible Preferred Stock into common stock
from December 31, 2017 to December 31, 2018
Issuance of Series C Convertible Preferred Stock into common stock, net
Conversion of Series C Convertible Preferred Stock into common stock
Conversion of Series B Convertible Preferred Stock into common stock
Cytori Therapeutics (NASDAQ:CYTX) ("Cytori" or the "Company") today announced that the Company effected a reverse stock split that became effective on May 23, 2018 at a ratio of one-for-ten, and that the Company's common stock will commence trading on a post-split basis beginning on May 24, 2018. The Company received the requisite stockholder approval for the reverse stock split on May 18, 2018. The new CUSIP number for the Company's common stock will be 23283K402.
from December 31, 2016 to December 31, 2017
Issuance of Series B Convertible Preferred Stock into common stock, net
Conversion of Series B Convertible Preferred Stock into common stock
Issuance of common stock under employee stock purchase plan
Sale of common stock, net
Issuance of common stock as part of Azaya Therapeutics acquisition, net
From December 31, 2015 to December 31, 2016
Issuance of common stock under employee stock purchase plan
Sale of common stock, net
On May 10, 2016, the Company effected a reverse stock split at a ratio of 1-for-15. All share and per share information presented herein has been retroactively restated to reflect the reverse split.
On May 10, 2016, the Company effected a reverse stock split at a ratio of 1-for-15. All share and per share information presented herein has been retroactively restated to reflect the reverse split.
from December 31, 2014 to December 31, 2015
Conversion of Series A 3.6% Convertible Preferred Stock into common stock
Issuance of common stock under stock option plan and employee stock purchase plan
Issuance of common stock under stock warrant agreement, net
Sale of common stock, net
From December 31,2013 to December 31,2014
Issuance of common stock under stock option plan and employee stock purchase plan
Sale of common stock, net
Issuance of Series A 3.6% Convertible Preferred Stock, net
Conversion of Series A 3.6% Convertible Preferred Stock into common stock
Issuance of common stock under stock warrant agreement
From December 31,2012 to December 31,2013
Issuance of common stock under stock option plan and employee stock purchase plan
Sale of common stock, net
from December 31, 2011 to December 31, 2012
Issuance of common stock under stock option plan and employee stock purchase plan
Issuance of common stock under stock warrant agreement
Sale of common stock, net
Issuance of common stock under stock option plan
Issuance of common stock under stock warrant agreement
Sale of common stock
from December 31, 2008 to December 31, 2009
Issuance of common stock under stock option plan
Issuance of common stock under stock warrant agreement
Sale of common stock
from December 31, 2007 to December 31, 2008
Issuance of common stock under stock option plan
Sale of common stock
from December 31, 2006 to December 31, 2007
Issuance of common stock under stock option plan
Sale of common stock
Sale of treasury stock
from December 31, 2005 to December 31, 2006
Issuance of common stock under stock option plan
Compensatory common stock awards
Issuance of common stock
Stock issued for license amendment
from December 31, 2004 to December 31, 2005
Issuance of common stock under stock option plan
Issuance of common stock under stock warrant agreement
Compensatory common stock awards
Issuance of common stock to Olympus